Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOakley Regulatory News (OCI)

Share Price Information for Oakley (OCI)

Share Price is delayed by 15 minutes
Get Live Data
524.00    4.00 (0.77%)
Bid:
524.00
Ask:
528.00
Spread: 4.00 (0.763%)
Market Cap: £867.04m
OCI Live PriceLast checked at - London Stock Exchange

Intraday Oakley Share Chart

Trading Update

29 Jan 2016 07:00

RNS Number : 3778N
Oakley Capital Investments Limited
29 January 2016
 

29 January 2016

 

 

Oakley Capital Investments Limited ("OCIL" or the "Company")

 

 

Trading Update for the 12 months ended 31 December 2015

 

 

· NAV per share (unaudited) expected to be in the range of £1.98 - £2.00 representing an increase of approximately 9% on June 2015

· Aggregate increase in fair value across both Fund portfolios of 31% (since June 2015)

· Oakley Funds have deployed €148m during 2015

· £77m invested by the Company in the period through its continuing co-investment programme facilitated by the £130m Placing in March 2015

· Successful exits returned €63m to the Company. Fund IRR generated of 64%

· Commitment of €250m to Fund III

 

Oakley Capital Investments Limited (AIM: OCL, "OCIL"), the AIM-listed company established to provide investors with access to the investment strategy being pursued by Oakley Capital Private Equity L.P. ("Fund I") and its successor fund, Oakley Capital Private Equity II ("Fund II") (together the "Funds"), today announces a trading update for the 12 months ended 31 December 2015.

 

The Company, through its investment in Fund I, has an indirect interest in each of Fund I's portfolio companies representing 65.5% of Fund I's total commitments; and through its investment in Fund II, an indirect interest in each of Fund II's portfolio companies representing 38.1% of Fund II's total commitments.

 

Oakley Capital Limited, OCIL's Investment Adviser, estimates that the Company's net asset value, which is subject to the completion of the 31 December 2015 audit of the Funds, and the Company, will be in the range of £378 million to £382 million, equating to a net asset value ("NAV") per share of between £1.98 to £2.00 (30 June 2015: £1.82). The overall increase in fair value across both Fund portfolios on a like-for-like basis is 31%, driven by strong portfolio company performances in Fund II. As at 31st December 2015, we expect the gross realised and unrealised returns to be 37% and 53% IRR and 2.2x and 1.6x money multiple for Fund I and Fund II's portfolio respectively. The OCIL net asset value is made up of cash, the investment in the Funds, co-investments, short-term bridging finance for the Funds and loans provided to a number of the portfolio companies.

 

Peter Dubens, Director, commented:

 

"The underlying performance of the Funds' portfolio companies has been strong over the period, reflected in the 31% growth in the fair value of their investment portfolios over the last six months, and driven by substantial EBITDA growth. The Funds had two exits in the period generating a combined gross IRR of 64%, providing good returns for our Investors.

 

We continue to see a dynamic pipeline of attractive investment opportunities which should enable the Funds and the Company to maintain their deployment record."

 

Key Highlights

· Fund I

o Fund I is fully invested and at the year end has just three portfolio companies remaining.

o The performance of this 2007 vintage fund has been extremely strong with a realised IRR of 46% and gross money multiple of 3.5x.

o In June 2015, Fund I disposed its controlling stake in Verivox to ProSieben, generating a gross money multiple of 14.5x and an IRR of 68%. Total proceeds of €56.3m were distributed to Fund investors, including €36.8m to the Company.

· Fund II

o Fund II is now 73% invested across nine portfolio companies.

o The portfolio of Fund II, which closed in December 2014 and hence is still relatively young, has seen an increase in its value to an IRR of 53% and gross money multiple of 1.6x (realised and unrealised).

o Fund II has made a total of nine investments, of which one has already been realised. The following new commitments were made during 2015:

- Damovo II Sarl, a provider of enterprise information communication technology (ICT) services and solutions, which will seek to replicate the success of Daisy through a European roll-up strategy led by founder of Daisy, Matthew Riley.

- Parship GmbH, one of Europe's earliest online dating businesses and the leading online matchmaker in Germany. Parship has a strong record of growth, which is continuing. Furthermore, shortly after the acquisition, the second player in the market, Elite Partner, was also acquired in an off market transaction which consolidates Parship's market position.

- Daisy Group Holding Limited ("Daisy") is the leading UK supplier of unified business communications and IT services and solutions. The Company is familiar with Daisy, having received considerable value when Fund I exited its 13.6% holding in Daisy in late 2014. The acquisition of Phoenix by Daisy provided an opportunity for Oakley to participate in its next strategic phase as a minority investor alongside the founder and chairman, Matthew Riley.

- Verivox, a market leader in Germany for online price comparison. Fund II had the opportunity to acquire a minority stake alongside ProSieben when Fund I exited, and therefore benefit from the synergies that will be achieved as well as the ongoing growth in this market. The Fund has a put option after five years.

Fund II has also benefitted from an exit and refinancing to return proceeds to fund investors:

- intergenia, the Fund's first investment, was sold to HEG Co. GmbH ("Host Europe"), the market leader, representing a gross money multiple of 1.4x and IRR of 47% for Fund II in under 12 months. Proceeds of €20.4m were distributed to the Company.

- facile, the leading Italian price comparison website acquired in 2013, was able to refinance its debt during the summer thanks to strong trading and cash generation, returning 20% of invested capital to the Fund, including €5.2m to OCIL.

· Co-investments:

During the year, the Company made co-investments and loans alongside the funds of £77million providing an efficient means of utilising the assets of OCIL in a prudent way. For the period since inception the IRR on OCIL's loans and cash has been in excess of 5% per annum.

· Commitment to Fund III

Following the new investments over the past 12 months, Fund II is now almost fully invested so OCIL has agreed to make, in line with its investing policy, a commitment of €250 million to Oakley Capital III, a successor fund.

Fund III will execute the same proven strategy as Oakley Capital Private Equity's previous Funds I and II.

· Capital Markets Day

OCIL will host a Capital Markets Day for institutional investors and analysts on 25th April 2016. A series of presentations will be given by the senior management team of the Company's Investment Adviser, Oakley Capital Limited, and by CEOs of several of the Limited Partnership's portfolio companies. No new material information will be disclosed.

 

- ends -

 

 

For further information please contact:

 

Oakley Capital Investments Limited

+44 20 7766 6900

Peter Dubens

 

Liberum Capital Limited (Broker & Nominated Adviser)

+44 20 3100 2000

Steve Pearce / Tom Fyson

 

FTI Consulting LLP

+44 20 3727 1000

Edward Bridges / Emily Desmier

 

 

About Oakley Capital Investments Limited ("OCL")

Oakley Capital Investments Limited is a Bermudan based company listed on AIM. OCL seeks to provide investors with long term capital appreciation through its investment in Oakley Capital Private Equity L.P. and Oakley Capital Private Equity II and through co-investment opportunities.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSEEEFAFMSEEF
Date   Source Headline
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
4th Apr 20257:00 amRNSTransaction in Own Shares
2nd Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20257:00 amRNSTotal Voting Rights
25th Mar 20253:16 pmRNSTransaction in Own Shares
24th Mar 20257:00 amRNSCapital Allocation Update
13th Mar 20257:00 amRNSFinal Results for the Year Ended 31 December 2024
26th Feb 20257:00 amRNSNotice of Results and Investor Presentation
5th Feb 20257:00 amRNSDirector Dealing
5th Feb 20257:00 amRNSDirector Dealing
3rd Feb 20257:00 amRNSDirector Dealing
29th Jan 20257:00 amRNSTrading update for the year ended 31 December 2024
20th Dec 202410:49 amRNSDirector Dealing
20th Dec 202410:48 amRNSDirector Dealing
19th Dec 20247:00 amRNSNorth Sails: Conversion of Equity
13th Dec 20247:00 amRNSDirector Dealing
13th Dec 20247:00 amRNSDirector Dealing
20th Nov 20247:00 amRNSOakley Capital invests in Konzept & Marketing
11th Nov 20247:00 amRNSHolding(s) in Company
8th Nov 20244:52 pmRNSHolding(s) in Company
6th Nov 20247:00 amRNSAppointment of Non-Executive Director
24th Oct 20247:00 amRNSOakley Capital agrees sale of Schülerhilfe to LLCP
23rd Oct 20247:00 amRNSTrading update for the 3 months ended 30 Sep 2024
21st Oct 20247:00 amRNSHolding(s) in Company
7th Oct 20247:00 amRNSOakley Capital invests in Assured Data Protection
12th Sep 20247:00 amRNSInterim Results for the 6 months ended 30 June 24
2nd Sep 20247:00 amRNSOakley agrees sale of Ocean to Lloyds Register
29th Aug 20247:00 amRNSNotice of Results and Investor Presentation
13th Aug 20247:00 amRNSDirector Dealing
26th Jul 20247:00 amRNSDirector Dealing
24th Jul 20247:00 amRNSTrading Update for the 6 Months ended 30 June 2024
17th Jul 20243:52 pmRNSHolding(s) in Company
28th Jun 20247:00 amRNSOakley agrees sale of its investment in idealista
11th Jun 20247:00 amRNSOakley to invest in cybersecurity firm I-TRACING
7th Jun 20247:00 amRNSDirector Dealing
3rd Jun 20243:43 pmRNSResult of AGM
28th May 20247:00 amRNSOakley Capital invests in ProductLife Group
14th May 20247:00 amRNSOakley Capital invests in vitroconnect
8th May 20247:00 amRNSNotice of Annual General Meeting
24th Apr 20247:00 amRNSTrading Update for the 3 months ended 31 March 24
2nd Apr 20244:17 pmRNSUpdate from QuotedData
27th Mar 20247:00 amRNSDirector Dealing
27th Mar 20247:00 amRNSDirector Dealing
26th Mar 20245:46 pmRNSHolding(s) in Company
26th Mar 20245:32 pmRNSHolding(s) in Company
18th Mar 20247:00 amRNSOakley Capital invests in Horizons Optical
15th Mar 20244:00 pmRNSQuotedData's Weekly News & Interview
14th Mar 20245:32 pmRNSDividend Declaration
14th Mar 20247:00 amRNSAnnual Results 2023

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.